B. Holkova

发表

Application of Neural Network Models in Modelling Economic Time Series with Non-constant Volatility

Lukas Falat, Zuzana Stanikova, M. Durisová, 2015 .

Proteasome inhibitors in mantle cell lymphoma.

S. Grant, B. Holkova, 2012, Best practice & research. Clinical haematology.

Bortezomib for the treatment of non-Hodgkin’s lymphoma

S. Grant, B. Holkova, P. Bose, 2014, Expert opinion on pharmacotherapy.

Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy.

K. Takeshita, A. Chanan-Khan, B. Holkova, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas

Derick R. Peterson, J. Friedberg, R. Fisher, 2016, Leukemia & lymphoma.

A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma

John D. Roberts, S. Grant, H. Sankala, 2017, Leukemia & lymphoma.

Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies

S. Grant, B. Holkova, 2011, Expert review of hematology.

Warfarin improves neuropathy in monoclonal gammopathy of undetermined significance

B. Holkova, Danielle M Noreika, E. D. Del Fabbro, 2016, BMJ Case Reports.

Refractory Anemia with Excess Blasts-2 Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or A Phase I Trial of Vorinostat and Alvocidib in Patients with

J. Supko, M. Ames, B. Holkova, 2013 .

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms

John D. Roberts, D. Coppola, S. Grant, 2011, Clinical Cancer Research.

Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.

S. Trudel, P. Richardson, N. Callander, 2021, Future oncology.

Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms

John D. Roberts, D. Coppola, S. Grant, 2014, Clinical Cancer Research.

Non-Hodgkin's lymphoma presenting as a breast mass in patients with HIV infection: A report of three cases

K. Takeshita, A. Chanan-Khan, A. Pavlick, 2005, Leukemia & lymphoma.

Effect o f H ighly A ctive A ntiretroviral T herapy o n S urvival in P atients W ith A IDS-Associated P ulmonary K aposi's Sarcoma T reated W ith C hemotherapy

K. Takeshita, A. Chanan-Khan, B. Holkova, 2001 .

Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update

John D. Roberts, G. Garcia-Manero, S. Grant, 2011 .

Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.

J. Friedberg, P. Flynn, B. Holkova, 2018 .

Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results

John D. Roberts, S. Grant, H. Sankala, 2014 .

Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma

M. Lunning, B. Holkova, A. Chari, 2018, Leukemia & lymphoma.

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.

J. Friedberg, B. Holkova, J. Goldschmidt, 2015, Blood.

Statistical Learning as a Tool for Optimizing the Level of Excise Tax of Mineral Oils in Slovakia

Lukas Falat, B. Holkova, Lukáš Falát, 2017 .

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

John D. Roberts, M. Raffeld, Hui-Yi Lin, 2015, Clinical Cancer Research.

A Phase II Trial of AZD 6244 ( Selumetinib , ARRY-142886 ) , an Oral MEK 1 / 2 Inhibitor , in Relapsed / Refractory Multiple Myeloma

John D. Roberts, M. Raffeld, Hui-Yi Lin, 2015 .

Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model

M. Czuczman, F. Hernandez-Ilizaliturri, B. Holkova, 2005, Clinical Cancer Research.

A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2

John D. Roberts, G. Shapiro, S. Grant, 2013, Clinical Cancer Research.

Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome

Elizabeth B. Collins, John D. Roberts, S. Dave, 2020, Leukemia & lymphoma.

Targeting Mantle Cell Lymphoma with a Strategy of Combined Proteasome and Histone Deacetylase Inhibition

S. Grant, B. Holkova, P. Bose, 2014 .

Clinical Characteristics of Gastrointestinal Lymphomas Associated with AIDS (GI-ARL) and the Impact of HAART

M. Czuczman, K. Takeshita, A. Chanan-Khan, 2004, HIV clinical trials.

A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer.

S. Steinberg, P. Choyke, M. Raffeld, 2015, Clinical colorectal cancer.

Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms

S. Grant, M. Rahmani, B. Holkova, 2017, Oncotarget.

Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

S. Trudel, P. Richardson, H. Nahi, 2020 .

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

P. Richardson, B. Holkova, J. Opalinska, 2019, Blood.

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B‐cell Lymphoma

John D. Roberts, C. Flowers, D. Coppola, 2018, Clinical lymphoma, myeloma & leukemia.

P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-5 STUDY

S. Lonial, P. Richardson, N. Callander, 2022, HemaSphere.

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

S. Trudel, P. Richardson, N. Callander, 2021, Blood.

Remission of rheumatoid arthritis on brentuximab vedotin.

B. Holkova, Nilanjana Bose, P. Bose, 2014, Rheumatology.

Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).

J. Burke, R. Advani, K. Kolibaba, 2015 .

T-cell clonality and myelodysplasia without chromosomal fragility in a patient with features of Seckel syndrome.

C. D. Wu, K. Takeshita, A. Chanan-Khan, 2003, Haematologica.

DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM).

P. Richardson, B. Holkova, J. Opalinska, 2020 .

A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results

J. Friedberg, B. Holkova, A. Forero-Torres, 2013 .

Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study

R. Advani, K. Kolibaba, S. Ansell, 2014 .

Bortezomib for the treatment of non-Hodgkin’s lymphoma

S. Grant, B. Holkova, P. Bose, 2014, Expert opinion on pharmacotherapy.

Review: erythroleukemia: clinical course and management.

A. Chanan-Khan, B. Holkova, Aisha Masood, 2010, Clinical advances in hematology & oncology : H&O.

Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)

Scott E. Smith, J. Burke, R. Advani, 2016 .